Autoantigen Vaccination In Human Type 1 Newly Diagnosed Diabetes Mellitus

Principal Investigator

Tihamer Orban, MD
Joslin Diabetes Center

Clinical Summary

This is a clinical study to investigate the safety and the immunologic response to an injection of human insulin B-chain in incomplete Freund's adjuvant (IFA) in humans.

With the ultimate goal of developing an intervention to prevent the immune destruction leading to beta-cell (insulin producing cell) loss, we will evaluate the clinical and immunological effects of this novel approach in participants with Type 1 diabetes (T1DM). The effects of this intervention on general immune responses, diabetes specific immune responses, and the deterioration of beta-cell function that occurs in T1DM will be studied in order to determine whether the vaccine alters immune responses associated with T1DM, and whether the vaccine has prolonged clinical efficacy. In this trial, we will also test, whether this novel approach can minimize or prevent long-term insulin dependence when administered to newly diagnosed diabetics.

Participating Clinical Sites

Joslin Diabetes Center, Boston, Massachusetts
Children's Hospital, Boston Massachusetts

Eligibility Requirements

We are currently seeking otherwise healthy men and women between ages 18-35 who have been diagnosed with type 1 diabetes mellitus less than three months. Candidates must not have a history of treatment with oral hypoglycemic agents or ongoing use of medications known to influence glucose tolerance nor; complications related to routine vaccinations nor; pregnancy or planned pregnancy within the time frame of the study nor; prior participation in trial for prevention of type 1 diabetes mellitus unless the individual is known to be in the placebo arm of a completed prior prevention trial.

Patient Enrollment Information

Eligible participants will receive at no charge:

• Physical examination
• Laboratory tests
• Study Vaccine
• Follow-up tests for 2 years

Monetary Compensation is available

To inquire about your eligibility and enrollment, please contact:

Heyam Jalahej M.D.
Clinical Trial Coordinator
Joslin Diabetes Center
One Joslin Place
Boston, MA 02215
Phone: 617-713-3463
E-mail:

June 2, 2003
Updated September 29, 2004

Not Helpful  1 2 3 4 5  Very Helpful                  E-mail Page     Print Format     Donate
			Jump to a new section --[ Getting Around ]-- Home Page What's New Guide to D123 Help with Error Messages Index Privacy Policy Search Site Map --[ People ]-- Family Support Network CWD Welcome Kit Adults with Diabetes Care Photos Chat Rooms Conferences Kids with Diabetes Parents Parent Humor Scholarships and Financial Aid Grandparents Humorous Tidbits Jobs Mailing Lists CWD Forums Poetry and Art Videos Polls Quilt for Life Surveys Blogs --[ Clinic ]-- Ask the Diabetes Team Alternate Site Testing Alternative Treatments Care Suggestions CWD Español Diabetes Basics Diabetes at School 504 Plans Diabetes Camps Diabetes Dictionary Insulin Pumps Nutrition Podcasts Presentations Products Product Marketplace Sports Studies Warning Signs --[ Sources ]-- News and Information Diabetes Advocacy Links to Other Web Sites Press Releases Regional Information Services Support Groups --[ Feedback ]-- About CWD and D123 Get CWD Products Advertise Awards Contribute Your Experiences Disclaimer Letters to the Editor Logos and Linking Share our Brochures

URL: http://www.diabetes123.com/d_0j_127.htm
Last Updated: Wed Sep 29 10:42:34 2004
Copyright © 1995-2007 Diabetes123 and Children with Diabetes. ALL RIGHTS RESERVED.
Terms of Service. Comments and Feedback. Disclaimer. Privacy statement.